Soy and Isoflavones Effect on Bone

NCT ID: NCT00668447

Last Updated: 2008-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

97 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-11-30

Study Completion Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the effect of 1 year of added dietary soy protein and/or soy isoflavones on bone mineral density in late postmenopausal women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although soy foods contain several components (isoflavones and amino acids) that could potentially have positive effects on bone health, there are few long term, large, clinical trials using soy as a means of improving bone mineral density. The objective of this study is to provide daily soy protein and isoflavones to healthy older women in order to answer three major questions:

1. Does soy protein alone affect bone metabolism?
2. Do isoflavones, given with soy protein, affect bone metabolism?
3. What dose of isoflavones affects bone in older women?

We hypothesize that soy protein will have a beneficial effect on bone in older women compared to control protein. Further, we hypothesize that there will be an additional benefit to bone in women who receive soy protein plus isoflavones (at both doses) compared to soy protein alone.

Both control and soy proteins used in the study were isolates, meaning they were the highest concentration of protein (85-90% by weight) in order to minimize the volume of protein supplement that each woman was asked to ingest on a daily basis. The soy protein was an alcohol-washed, soy protein isolate containing 90% protein and negligible isoflavone (0.2 mg/g product). The control protein was a mix consisting of 50% protein from sodium caseinate, 25% protein from whey protein and 25% from egg white protein. The use of a mix of proteins as a control provides a more balanced level of amino acids, mimics the real life mix of proteins that humans typically consume, and avoids the unique characteristics of one source of protein. In order to maintain the dietary protein intake constant, the participant was counseled to decrease her intake of other sources of protein from primarily animal sources by approximately 3 ounces per day (the approximate equivalent of the protein powders). The isoflavones tablets each contained 57 mg of total isoflavone from primarily genistein, glycitein, and daidzein and their beta-glycosides.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

bone density bone loss postmenopausal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Soy protein and isoflavone tablets

Group Type EXPERIMENTAL

Soy Isolate

Intervention Type DIETARY_SUPPLEMENT

20 grams of powder mixed in beverages or food daily for one year

Novasoy isoflavones

Intervention Type DIETARY_SUPPLEMENT

3 tablets daily for one year

2

Soy protein and placebo tablets

Group Type ACTIVE_COMPARATOR

Soy Isolate

Intervention Type DIETARY_SUPPLEMENT

20 grams of powder mixed in beverages or food daily for one year

Placebo tablets

Intervention Type DIETARY_SUPPLEMENT

3 tablets daily for one year

3

control protein and Isoflavone tablets

Group Type ACTIVE_COMPARATOR

Control protein

Intervention Type DIETARY_SUPPLEMENT

20 grams of powder mixed in beverages or food daily for one year

Novasoy isoflavones

Intervention Type DIETARY_SUPPLEMENT

3 tablets daily for one year

4

control protein and placebo tablets

Group Type PLACEBO_COMPARATOR

Control protein

Intervention Type DIETARY_SUPPLEMENT

20 grams of powder mixed in beverages or food daily for one year

Placebo tablets

Intervention Type DIETARY_SUPPLEMENT

3 tablets daily for one year

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soy Isolate

20 grams of powder mixed in beverages or food daily for one year

Intervention Type DIETARY_SUPPLEMENT

Control protein

20 grams of powder mixed in beverages or food daily for one year

Intervention Type DIETARY_SUPPLEMENT

Novasoy isoflavones

3 tablets daily for one year

Intervention Type DIETARY_SUPPLEMENT

Placebo tablets

3 tablets daily for one year

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pro Fam 930, 066-930

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women 65 years old or older
* Able to travel to the clinical sites for follow-up visits

Exclusion Criteria

* History of disease that may affect bone metabolism (including Paget's disease, primary hyperparathyroidism, osteomalacia, untreated hyperthyroidism, or multiple myeloma)
* Cancer of any kind (except basal or squamous cell of skin) in past 5 years
* Use of any of the following medications within the past 2 years: calcitonin, calcitriol, heparin, phenytoin, phenobarbital
* Use at any time of bisphosphonates, long-term corticosteroids (over 6 months), methotrexate, or fluoride
* Estimated creatinine clearance less than 50 ml/min
* History of chronic liver disease or evidence of liver disease on screening
* History of hip fracture
* Known vertebral fracture within the past year
* Vegans
Minimum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Connecticut

OTHER

Sponsor Role collaborator

United States Department of Agriculture (USDA)

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Connecticut Center on Aging

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jane Kerstetter, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Allied Health Sciences, University of Connecticut

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Connecticut Health Center

Farmington, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT. Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause. 2007 May-Jun;14(3 Pt 1):481-8. doi: 10.1097/01.gme.0000243570.78570.f7.

Reference Type BACKGROUND
PMID: 17213752 (View on PubMed)

Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000 Sep;72(3):844-52. doi: 10.1093/ajcn/72.3.844.

Reference Type BACKGROUND
PMID: 10966908 (View on PubMed)

Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J, Arquitt AB, Payton ME, Mason C. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J. 2005 Feb 23;4:8. doi: 10.1186/1475-2891-4-8.

Reference Type BACKGROUND
PMID: 15727682 (View on PubMed)

Kenny AM, Mangano KM, Abourizk RH, Bruno RS, Anamani DE, Kleppinger A, Walsh SJ, Prestwood KM, Kerstetter JE. Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr. 2009 Jul;90(1):234-42. doi: 10.3945/ajcn.2009.27600. Epub 2009 May 27.

Reference Type DERIVED
PMID: 19474141 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

USDA CONR-2001-00630

Identifier Type: -

Identifier Source: secondary_id

AG0102

Identifier Type: -

Identifier Source: org_study_id